drugset / Trial / NCT04387695
SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate and compare the efficacy and safety of SBRT sequential TACE combined with sorafenib versus sorafenib alone in the treatment of unreactable HCC with PVTT.
Timeline
- Start
- 2020-04-30
- Primary completion
- 2023-08-01
- Completion
- 2023-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Sorafenib | Small molecule | 800 mg | Oral |